Understand the source comparison
AICAR versus direct/allosteric activators
Newer synthetic AMPK activators (such as the ADaM-site binders developed by several pharmaceutical programs) bind AMPK directly and selectively, avoiding the off-target AMP-mimetic effects of ZMP.[5] Their existence is part of why AICAR is increasingly a legac
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Newer synthetic AMPK activators (such as the ADaM-site binders developed by several pharmaceutical programs) bind AMPK directly and selectively, avoiding the off-target AMP-mimetic effects of ZMP.[5] Their existence is part of why AICAR is increasingly a legacy tool rather than a drug candidate: if the goal is clean AMPK activation, better molecules now exist.